Swine Flu Vaccine Safety Questions

I began this blog at the start of the Swine Flu Frenzy in 2009 as link repository for stories relating to negative effects of the H1N1 vaccines around the world. The initial wave of hysteria has diminished, but the stories questioning the safety of this new wave of of H1N1 and Flu Vaccinations continue. As long as they do, this blog will be updated. Ultimately one must work with their doctor and use their own judgment around whether or not to vaccinate against the flu.

Wednesday, November 18, 2009

British Columbia sees spike in severe reactions to flu shot

As Canadian health officials assured the public that the pandemic H1N1 vaccine is as safe as the seasonal flu shot, at least one province is reporting almost double the rate of severe allergic reactions.

READ MORE HERE:
http://www.theglobeandmail.com/life/health/h1n1-swine-flu/bc-sees-spike-in-severe-reactions-to-flu-shot/article1367348/

Terms You Should Know

Adjuvant- In immunology, an adjuvant is an agent that may stimulate the immune system and increase the response to a vaccine, without having any specific antigenic effect in itself. (definition from wikipedia)

Two Adjuvant that may be used in the Swine Flu Vaccines that are cause for concern: MF59 and ASO3

“……Vaccines containing MF59 and ASO3 have not had Emergency Use Authorizations issued for them--yet. However, the government has purchased $698 million dollars' worth of these adjuvants in recent weeks.

http://www.hhs.gov/news/press/2009pres/07/20090713b.html https://

and WHO officials have indicated the likelihood of their use, which is the only way to achieve adequate amounts of vaccine for the US and world population in the fall.…..These vaccines have never been demonstrated to be safe in children, pregnant women or young adults. They have not undergone comprehensive testing; for example, MF59 has not and will not be tested for carcinogenicity by the manufacturer.
(See page 391)
http://www.fda.gov/downloads/BiologicsBloodVaccines/NewsEvents/WorkshopsMeetingsConferences/ucm095708.pdf